company background image
STOK logo

Stoke Therapeutics NasdaqGS:STOK Voorraadrapport

Laatste prijs

US$11.27

Marktkapitalisatie

US$599.1m

7D

-19.0%

1Y

190.5%

Bijgewerkt

21 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Stoke Therapeutics, Inc.

NasdaqGS:STOK Voorraadrapport

Marktkapitalisatie: US$599.1m

STOK Overzicht aandelen

Stoke Therapeutics, Inc., een biofarmaceutisch bedrijf in een vroeg stadium, ontwikkelt medicijnen om de onderliggende oorzaken van ernstige genetische ziekten in de Verenigde Staten te behandelen. Meer informatie

Stoke Therapeutics, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Stoke Therapeutics
Historische aandelenkoersen
Huidige aandelenkoersUS$11.27
52 Week HoogtepuntUS$17.58
52 Week LaagUS$3.77
Bèta0.95
11 maand verandering-9.98%
3 maanden verandering-19.44%
1 Jaar Verandering190.46%
33 jaar verandering-59.23%
5 jaar verandering-54.85%
Verandering sinds IPO-55.92%

Recent nieuws en updates

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Recent updates

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 07

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Jul 22
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 14

It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

May 30
It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

Apr 04

Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

Mar 21
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation

We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Dec 07
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

May 09
Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts

Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

May 06
Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results

Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

May 02
Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business

We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Dec 13
We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow

Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Aug 14
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth

Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M

Aug 08

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Apr 29
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

Jan 13
Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

Sep 30
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Jun 16
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Stoke Therapeutics EPS misses by $0.02

May 10

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Rendement voor aandeelhouders

STOKUS BiotechsUS Markt
7D-19.0%-3.7%0.3%
1Y190.5%15.2%31.1%

Rendement versus industrie: STOK overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 14.6 % opleverde.

Rendement versus markt: STOK overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.3 %.

Prijsvolatiliteit

Is STOK's price volatile compared to industry and market?
STOK volatility
STOK Average Weekly Movement8.4%
Biotechs Industry Average Movement9.8%
Market Average Movement6.2%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: STOK heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van STOK is het afgelopen jaar gedaald van 15% naar 8%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2014110Ed Kayewww.stoketherapeutics.com

Stoke Therapeutics, Inc., een biofarmaceutisch bedrijf in een vroeg stadium, ontwikkelt medicijnen om de onderliggende oorzaken van ernstige genetische ziekten in de Verenigde Staten te behandelen. Het bedrijf gebruikt zijn gepatenteerde doelgerichte verhoging van de productie van nucleaire genen om antisense oligonucleotiden te ontwikkelen die selectief de eiwitniveaus herstellen. De belangrijkste klinische kandidaat is STK-002, dat zich in een preklinisch stadium bevindt voor de behandeling van autosomaal dominante optische atrofie.

Stoke Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Stoke Therapeutics zich tot de beurswaarde?
STOK fundamentele statistieken
MarktkapitalisatieUS$599.06m
Inkomsten(TTM)-US$105.46m
Inkomsten(TTM)US$16.74m

35.7x

P/S-verhouding

-5.7x

Koers/Winstverhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
STOK resultatenrekening (TTM)
InkomstenUS$16.74m
Kosten van inkomstenUS$0
BrutowinstUS$16.74m
Overige uitgavenUS$122.20m
Inkomsten-US$105.46m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-1.99
Brutomarge100.00%
Nettowinstmarge-629.86%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde STOK op de lange termijn?

Bekijk historische prestaties en vergelijking